Perflexane (AF0150, AFO 150, Imagent, Imavist).
D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003287:Contrast Media / Q000009:adverse effects; D003326:Coronary Circulation / Q000502:physiology; D017277:Drug Approval; D004699:Endocardium / Q000473:pathology; D005466:Fluorocarbons / Q000009:adverse effects; D006801:Humans; D006842:Hydrocarbons, Brominated / Q000009:adverse effects; D018810:Magnetic Resonance Angiography; D008297:Male; D008863:Microspheres; D011471:Prostatic Neoplasms / Q000473:pathology
D003287:Contrast Media; D005466:Fluorocarbons; D006842:Hydrocarbons, Brominated; C078626:perflexane